Helsinn Healthcare SA NK-1 Antagonist Patent Granted Apr 21
Summary
USPTO granted Patent US12606527B2 to Helsinn Healthcare SA on April 21, 2026, for crystalline forms of an NK-1 antagonist useful in treating induced vomiting and other disorders. The patent application (18772244) was filed July 14, 2024, and contains 18 claims classified under CPC C07D 213/75 and related pharmaceutical categories.
What changed
USPTO granted Patent US12606527B2 to Helsinn Healthcare SA for crystalline NK-1 antagonist compounds. The patent provides exclusive rights to the assignee for the pharmaceutical composition effective from the July 2024 filing date.
Pharmaceutical companies developing antiemetic therapies should evaluate whether their products or development programs may overlap with the patented crystalline forms. Generic or biosimilar manufacturers may wish to assess potential invalidity or non-infringement positions relative to the 18 granted claims.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Crystalline forms of an NK-1 antagonist
Grant US12606527B2 Kind: B2 Apr 21, 2026
Assignee
Helsinn Healthcare SA
Inventors
Christian Bacilieri, Gionata Frasca
Abstract
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
CPC Classifications
C07D 213/75 C07D 401/04 A61P 1/08 A61P 25/00 A61P 35/00 A61P 43/00 C07B 2200/13 A61K 31/444 A61K 31/496
Filing Date
2024-07-14
Application No.
18772244
Claims
18
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.